UNSPSC 51272107: Metabutethamine

This classification denotes an anesthetic agent with the molecular formula C13H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PSJ9VIF3RV, chemically known as ethanol, 2- (isobutylamino)-, m-aminobenzoate (ester), monohydrochloride but generally known as metabutethamine, which bears US NIH Compound Identifier 11115. World Health Organization schedules metabutethamine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, METABUTETHAMINE remains the US FDA Preferred Term for this commodity.

Metabutethamine bears US NLM identifiers UMLS ID C0301289 and NCI Concept Code C81413. SMILES: CC(C)CNCCOC(=O)C1=CC(=CC=C1)N.

UNSPSC 51272107 Metabutethamine is a Commodity code. Recent state and local procurement activity under this code focuses on pharmaceutical and over-the-counter product procurement, though the opportunities posted do not directly address metabutethamine itself. Instead, issuing bodies are sourcing naloxone, generic pharmaceuticals, and drug deactivation systems through competitive and cooperative purchasing vehicles. Seminole County, Florida, for example, issued IFB 60459723LAS seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to county community health facilities. The Texas Health and Human Services Commission posted RFI HHS0017013 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for generic multi-source pharmaceuticals and OTC products distributed to participating state and local government facilities across multiple states including Oregon. These solicitations reveal that state and local governments use this code family for supply of pharmaceutical products, controlled-substance antagonists, and medical supplies through both direct procurement and cooperative purchasing frameworks, with emphasis on compliance with FDA regulations, cGMP certification, and Drug Supply Chain Security Act requirements.

Activity is concentrated in Florida, Texas, and Minnesota as of early 2026, with the MMCAP cooperative purchasing vehicle extending reach across multiple states. Seminole County's IFB (posted June 30, 2026, due July 26, 2026) targets quarterly delivery of naloxone and drug deactivation systems to support community health initiatives and requires fixed-price bidding with drug-free workplace and E-Verify compliance. The MMCAP RFP (posted January 20, 2026, due March 26, 2026) establishes multi-award contracts effective July 1, 2026, with pricing evaluation weighted 75 percent toward price competitiveness and requirements for EDI capability, cGMP and DSCSA compliance, and relationships with authorized wholesalers. The Texas RFI (posted April 3, 2026, closed April 3, 2026) functions as exploratory market research preceding a formal RFP and seeks vendor experience with direct contracting for self-insured employers and government health plans using negotiated net pricing. No explicit set-aside designations are noted across these solicitations, and budget ranges are not disclosed in the available documentation.